Format

Send to

Choose Destination
Int J Clin Exp Pathol. 2015 Sep 1;8(9):10615-24. eCollection 2015.

Golgi phosphoprotein3 overexpression is associated with poor survival in patients with solid tumors: a meta-analysis.

Author information

1
Department of Oncology, Subei People's Hospital, Yangzhou University Yangzhou 215002, Jiangsu, China.
2
Department of Oncology, The First People's Hospital of Yueyang Yueyang 414000, Hunan, China.
3
Department of Oncology, Nanfang Hospital, Southern Medical University Guangzhou, Guangdong 510515, China.

Abstract

Golgi phosphoprotein3 (GOLPH3) is known as an oncoprotein and may be a prognostic biomarker in various tumors. Here we performed a meta-analysis on the association of GOLPH3 expression and survival in solid tumors. All eligible studies were identified in Embase, PubMed and Web of Science Databases up to November 2014. Data about overall survival (OS), and disease-free survival (DFS) were extracted and pooled hazard ratios (HRs) of GOLPH3 for survival were calculated by using a random-effect model. Heterogeneity and publication bias were also assessed. A total of 15 eligible studies which comprised of 2529 cases were included in this global analysis: 14 were dealing with overall survival (OS) and 6 were with disease-free survival (DFS). We found that GOLPH3 overexpression was associated with shorter OS (HR 2.487, 95% CI 1.897-3.258, P < 0.001) and DFS (HR 1.911, 95% CI 1.245-2.932, P = 0.003) in general carcinomas. Importantly, subgroup analysis suggested that overexpression of GOLPH3 correlated with shorter OS in urogenital system cancers (HR 4.258, 95% CI 1.81-4.91, P < 0.001). Moreover, publication bias was not significant (P > 0.05). In conclusion, the present meta-analysis showed that overexpression of GOLPH3 predicts poor prognosis in solid tumors.

KEYWORDS:

Golgi phosphoprotein3; meta-analysis; prognosis; solid tumors

PMID:
26617771
PMCID:
PMC4637586
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center